<DOC>
	<DOCNO>NCT01851707</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy multiple dose level investigational product ( study drug ) , IPI-145 , combination methotrexate compare methotrexate alone subject active moderate-to-severe Rheumatoid Arthritis .</brief_summary>
	<brief_title>A Double-Blind Study Evaluating Duvelisib Subjects With Moderate Severe Rheumatoid Arthritis Inadequate Response Methotrexate Alone</brief_title>
	<detailed_description>This Phase 2 study design examine efficacy safety multiple dose level IPI-145 subject active moderate-to-severe Rheumatoid Arthritis receive background stable dose methotrexate . The study employ randomize , double-blind , placebo-controlled , parallel design . Approximately 316 adult subject meet eligibility criterion Screening randomized Baseline 1:1:1:1 ratio one 4 dose group . All treatment administer twice day ( BID ) . After randomization , subject enter 12-week Treatment Period , study drug ( IPI-145 placebo ) self-administered BID outpatient . During Treatment Period , subject return clinic efficacy safety assessment every 2 week . Following Treatment Period completion Week 12 , subject enter 3-week Follow-up Period include one clinic visit approximately 3 week last dose study drug .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Documented diagnosis Rheumatoid Arthritis least 6 month Active disease , base Screening clinical laboratory criterion , despite take methotrexate least 3 month Pregnant lactate female Previous failure inadequate response &gt; 2 biologic diseasemodifying antirheumatic drug ( DMARDs ) Concurrent DMARD treatment methotrexate , sulfasalazine , chloroquine , hydroxychloroquine Treatment &gt; 10 mg daily prednisone ( equivalent ) one nonsteroidal antiinflammatory drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>